logo
First Came Ozempic Face. Now People Are Dealing With Ozempic Hair and Muscle Loss

First Came Ozempic Face. Now People Are Dealing With Ozempic Hair and Muscle Loss

Voguea day ago
Ever since Ozempic flooded the mainstream consciousness, the controversial weight loss drug of choice has come with some well-documented downsides. Many have dealt with the infamous Ozempic face, which experts describe as rapid weight loss to the face and loss of elasticity in the skin, causing one to look much older. 'Ozempic face can look gaunt, deflated, and saggy,' New York-based facial plastic surgeon Dr. Jennifer Levine once told Vogue. 'Think raisin as opposed to grape!'
Now, people are noticing that Ozempic and similar GLP-1 drugs (Mounjaro, Wegovy, Rybelsus, and Zepound, to name a few) are affecting their hairline and possibly weakening their muscle strength. So what gives?
Why is this happening?
Though some studies link these drugs to hair loss, experts still say it is not a direct side effect of GLP-1s like Ozempic or other medications like Mounjaro. Marisa Garshick, MD, board-certified dermatologist at MDCS Dermatology, explains that it's actually more of an indirect result of rapid weight loss, nutritional deficiencies, or stress on the body. 'Telogen effluvium is a type of hair shedding that may be noticed a few months after the body experiences some type of change or stress,' says Dr. Garshick (it's akin to the dramatic hair shedding some saw in the months post-COVID-19). 'People on GLP-1s may not actually notice hair shedding or thinning for several months after they are on it.'
As for muscle loss—that's just a general side effect of losing weight, regardless of whether the impetus is diet, exercise, surgery, or a medication like Ozempic. Holly Lofton, MD, director of the medical weight management program at NYU Langone Health, tells Vogue that experts see medications like Wegovy and Zepbound are causing the same—and sometimes more—amount of muscle loss as one might experience through more traditional weight loss methods. Studies show that 25 to 30% of the total weight loss caused by calorie restriction and exercise comes from lean body mass, which includes muscles. So if someone were to lose 20 pounds, she says around 5 to 6 pounds of that might be muscle that is lost. Studies on medications like Wegovy and Zepbound show patients can lose roughly 15 to 22% of their total weight, with about 25% of that weight loss being lean muscle mass. 'These drugs are not necessarily muscle-sparing,' she says. 'However, because people tend to lose more total weight on these medications, the absolute amount of muscle loss can be greater (unless we intervene with resistance training and adequate protein intake).'
What can you do about it?
There are a few things you can do to treat hair and muscle loss that you might experience when on these medications. Dr. Garshick says that it is normal to shed about 50 to 100 hairs a day, so you should only be concerned if you notice significantly more hair falling out or if your hair loss persists longer than three to six months. If that is the case, she recommends seeing a board-certified dermatologist to be properly evaluated. 'Since telogen effluvium is considered a temporary process, once the weight stabilizes, it is possible the hair loss will slow down and hair regrowth will resume and normalize even without doing any specific intervention,' she says. 'While this process can take six to 12 months, providing reassurance that it can get better on its own is often sufficient.'
She says getting bloodwork done to see if there are hormonal changes or nutritional deficiencies that can be addressed through diet (making sure you are consuming enough protein is key) or the use of oral supplements like Nutrafol or Wellbell. You can also turn to thickening and volumizing shampoos, like the Nioxin Hair Fall Defense Shampoo or the Vegamour GRO Revitalizing Shampoo, and leave-in products like the Virtue Flourish Density Booster, to help increase hair density. For more intense treatments, you can inquire about platelet-rich plasma (PRP) therapy to stimulate hair growth.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lawmakers Press FDA to Target Compounded, Fake Weight-Loss Drugs
Lawmakers Press FDA to Target Compounded, Fake Weight-Loss Drugs

Bloomberg

time7 hours ago

  • Bloomberg

Lawmakers Press FDA to Target Compounded, Fake Weight-Loss Drugs

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year.

Semaglutide improves brain-related injury patients' outcomes
Semaglutide improves brain-related injury patients' outcomes

Yahoo

time8 hours ago

  • Yahoo

Semaglutide improves brain-related injury patients' outcomes

GLP-1R agonist semaglutide, also known as Ozempic or Wegovy, has been making headlines for its potential in its original market - the treatment of Type 2 diabetes - for its weight loss effects and benefits in other metabolic disorders, and for its possible expansions into new therapeutic areas. Most recently, results from different studies have suggested that semaglutide may improve patient outcomes following brain haemorrhage or stroke. GlobalData estimates that semaglutide's benefits may be connected to a reduction of inflammation in the body and brain. As mentioned in GlobalData's report: GLP-1R Agonist - Label Expansions/Drug Repurposing: Market Overview, Ozempic is currently in Phase II trials for acute ischaemic stroke. Other GLP-1R agonists and combination therapies are in clinical development for other neurological conditions, and many academic studies are currently focusing on the potential use of GLP-1R agonists in stroke to reduce complications and the risk of recurrence altogether. In July 2025, new results have emerged from three studies investigating the use of semaglutide in stroke and brain haemorrhage patients. A study by the University of Wisconsin-Madison revealed that the chance of surviving after a stroke was higher in patients on semaglutide, and death from stroke was more frequent in the patient group not on a GLP-1R agonist. Another study by the same university examining a US nationwide sample of hospital records found an association between the use of GLP-1R agonists and a reduction in stroke complications. A third study by the University of Texas Medical Branch in Galveston suggested that semaglutide use was linked to a reduced risk of side effects, seizures, future recurrence and death after brain haemorrhage and stroke. The SELECT trial has demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its benefits in stroke patients. Furthermore, the occurrence of stroke is linked to metabolic health, inflammation and obesity, so an improvement in these factors can benefit patients likely to experience a stroke or who have done so in the past. According to key opinion leaders interviewed by GlobalData, the potential of GLP-1R agonists in brain diseases seems to be based on their anti-inflammatory action. Indeed, GLP-1R agonists are known to improve insulin sensitivity and reduce insulin resistance, and it seems that this translates to the brain too, as these molecules can cross the blood-brain barrier. Cerebrovascular conditions such as stroke and brain hemorrhage appear to benefit from both the cardiovascular benefits and cerebral anti-inflammatory health benefits associated with GLP-1R agonists' use, on top of the improvement in overall health. Therefore, GLP-1R agonists may successfully penetrate not one but multiple neurological diseases markets, if their effects are proven to be significant and worth the cost of these medicines. "Semaglutide improves brain-related injury patients' outcomes" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

GLP-1s Only Opening Act: Experts Unveil Diet-Exercise Guide
GLP-1s Only Opening Act: Experts Unveil Diet-Exercise Guide

Medscape

time12 hours ago

  • Medscape

GLP-1s Only Opening Act: Experts Unveil Diet-Exercise Guide

The weight loss seen with GLP-1 receptor agonists is only half the story. Long-term success hinges on integrating medication with individualized nutrition and physical activity counseling, a trio of experts remind clinicians in a new paper. GLP-1 medications and dual receptor agonist medications are 'very effective in terms of weight loss, achieving about 20% weight loss or more,' JoAnn Manson, MD, MPH, professor of medicine, Harvard Medical School and Brigham and Women's Hospital, both in Boston, told Medscape Medical News . However, the loss of muscle mass and lean body mass is also 'quite common, sometimes accounting for 25% or more of the total weight loss.' Lifestyle factors are 'crucial' to optimize outcomes for patients on GLP-1 medications, Manson said. She and her coauthors offered advice on integrating diet and physical activity and managing potential side effects in patients with obesity starting a GLP-1 medication in a brief two-page 'Clinical Insights' article in JAMA Internal Medicine. There is also companion 'Patient Page.' Monitor Weight Loss Clinicians should track weight monthly during GLP-1 dose escalation and at least quarterly thereafter, intervening if patients lose too little or too much weight, the authors advised. For those with < 5% weight loss after 12-16 weeks, options include continuing standard dose escalation and documenting progress, given that standard titration periods (at least 17 weeks) may not work for all individuals; checking for missed doses and adjust dose titration as needed to maximize adherence; or switching to an alternative GLP-1 drug if the maximum tolerated dose is not effective, they said. It's also important to monitor for excessive weight loss, the authors said. Indications that weight loss may be excessive or harming overall health include a BMI < 18.5, anorexia (consuming < 800 calories/d), or very low protein intake. In a patient with excessive weight loss, it's important to rule out secondary causes such as eating or endocrine disorders or malignant tumors, assess for correlated harms including nutrient deficiencies and hormonal imbalances, assess psychological function with referrals to specialists as needed, and consider dose reduction or stopping the medication temporarily, the author advised. Assess Diet, Manage Nutrient Intake If available, patients should see a registered dietitian initially, with follow-up visits every 2-3 months during dose escalation. If this is not feasible, clinicians can administer the Rapid Eating Assessment for Participants-Shortened, a brief nutritional assessment tool. The authors emphasized that nutrient quality is more important than rigid calorie counting. However, patients may also benefit from periodic tracking of their food and fluid intake through smartphone applications, manual food logs or taking photos of their food to help guide dietary adjustments. For patients comfortable with tracking their calories, target calorie ranges should be individualized based on weight goals and activity level. To minimize muscle loss, patients should be advised to maintain adequate protein intake of 60-75 g/d (1.0-1.5 g/kg; > 1.5 g/kg for older or post-bariatric surgery patients) and engage in structured physical activity (aerobic and strength training). To maintain energy balance, smaller, nutrient-dense meals rather than calorie restriction is advised. Whole grains for satiety and sustained energy and healthy fats to support fat-soluble vitamin absorption and reduce cholestasis are recommended. Manson noted that 'gastrointestinal symptoms — such as nausea, constipation, and reflux — can limit the use of these medications, lead to drug discontinuation, and subsequently results in weight regain.' To help ward off constipation, patients should be advised to increase fiber intake and take in more than 2-3 L of fluid a day and use over-the-counter laxatives if needed. For nausea, they should avoid fried foods and carbonated drinks. For reflux, eating smaller portions, not lying down for 2-3 hours after meals and limiting high-fat and irritating spices may help. Because appetite suppression induced by GLP-1 medications can unmask hidden micronutrient deficiencies, clinicians could consider assessment of vitamin D, iron, B-vitamins, and other micronutrients and add a multivitamin when intake is chronically low, the authors said. Physical Activity: Start Slow and Add-On The authors recommend a three-step approach to counseling patients on physical activity. First, introduce regular movement gradually and work up to 150 minutes of moderate (or 75 min of vigorous) activity weekly. Second, incorporate resistance training, aiming for 60-90 min/wk. Third, maintain 30-60 minutes per day of aerobic exercise combined with resistance training two to three times per week for optimal long-term weight and metabolic outcomes. Balance and mobility training for older adults can be especially helpful, the author said. Clinicians may also consider assessing muscle strength and function, such as the grip strength or 6-minute walk test, the authors said. Weight Regain Patients who discontinue GLP-1 therapy may regain weight and this should be discussed with patients at the start of treatment, the authors said. Specifically, in randomized controlled trials, weight rebound of roughly 7%-12% has been observed within 1 year of stopping GLP-1 therapy and that lifestyle habits put in place early will be the main defense if dose reductions or discontinuation are attempted. The authors noted that all patients will reach a weight-loss plateau, but weight maintenance protocols for GLP-1 drugs have yet to be established. 'Clinicians should base treatment decisions on the premise that obesity is a chronic condition typically requiring long-term management, similar to hypertension,' they advised. When a decision to taper the medication is made, options include reducing the dose or frequency of injections or tapering off treatment completely with progressively less monitoring (weekly to biweekly, followed by monthly, then quarterly) over at least 20 weeks. 'Clinicians should continue to assess weight, metabolic health, diet and activity levels, appetite, sleep patterns, mood changes, and muscle strength. Medication reinitiation or dose increase should be considered if weight regain exceeds 5%,' they advised. Manson told Medscape Medical News she hopes this information will be a 'good resource that will result in better care for patients on GLP-1 medications and better outcomes.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store